PartnershipJul 9, 2026, 04:02 PM
Nurix inks $2.3B potential deal with Roche for bexobrutideg, $700M upfront
AI Summary
Nurix Therapeutics announced a global collaboration agreement with Roche for its BTK degrader bexobrutideg, with potential total payments of up to $2.3 billion, including a $700 million upfront payment. This partnership will co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology, including planned Phase 2 studies in multiple sclerosis and chronic spontaneous urticaria. The company also reported a net loss of $89.5 million for the fiscal second quarter ended May 31, 2026, on revenue of $9.0 million. Nurix's pro-forma cash position is approximately $1.14 billion, significantly bolstered by the expected upfront payment.
Key Highlights
- Global collaboration with Roche for bexobrutideg, with potential total payments up to $2.3 billion.
- Nurix to receive a $700 million upfront payment from Roche.
- Co-development and co-commercialization of bexobrutideg across hematology, immunology, and neurology.
- Q2 2026 revenue was $9.0 million, compared to $44.1 million in Q2 2025.
- Q2 2026 net loss was $89.5 million, or ($0.81) per share.
- Cash, cash equivalents, and marketable securities were $443.5 million as of May 31, 2026.
- Pro-forma cash approximately $1.14 billion, including the Roche upfront payment.
- Research and development expenses increased to $87.7 million in Q2 2026.
Price Impact
More from NRIX